相关实验视频
Updated: Sep 10, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
在TITAN和SPARTAN试验中治疗晚期前列腺癌的患者
Soumyajit Roy1, Zeynep Irem Ozay2, Avirup Guha3,4
1Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
在接受阿帕胺治疗的前列腺癌患者中,使用静止剂与整体存活率 (OS) 的改善有关. 然而,他类药物使用者面临的严重心脏事件的风险更高,可能是由于潜在的健康状况.
科学领域:
- 癌症学
- 心脏病学
- 临床试验
背景情况:
- 在强化阿帕胺治疗的前列腺癌患者中,他类药物对整体存活率 (OS) 的影响尚不清楚.
- 了解这种关联对于优化治疗策略至关重要.
研究的目的:
- 研究阿帕胺治疗患者的他类药物暴露与生存状况之间的关系.
- 在该患者群体中评估他类药物使用与严重心脏不良事件 (AE) 之间的关联.
主要方法:
- 一项从两个第三阶段随机试验 (SPARTAN和TITAN) 中分析个体患者数据的队列研究.
- 使用治疗权重的逆概率 (IPTW) 和Cox比例危险模型进行OS分析.
- 采用精细和灰色回归模型来评估心脏副作用的风险,并考虑相应的死亡风险.
主要成果:
- 在接受阿帕胺治疗的患者中,静止剂暴露与更高的生存率有关 (HRs 范围为0. 53至0. 54).
- 在安慰剂组中没有观察到显著的生存效益 (HR为0. 65和1. 16).
- 在阿帕胺和安慰剂组中,使用他类药物的心脏副作用的风险增加 (分别为2. 62和2. 36).
结论:
- 在接受阿帕胺治疗的前列腺癌患者中,静止剂暴露与改善的生存状况相关.
- 在他类药物使用者中,心脏副作用的风险增加可能归因于先前存在的心血管并发症.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Atherosclerosis III: Management